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An integrative network analysis 
framework for identifying 
molecular functions in complex 
disorders examining major 
depressive disorder as a test case
Anup Mammen Oommen1,4, Stephen Cunningham1,4*, Páraic S. O’Súilleabháin2,5, 
Brian M. Hughes3 & Lokesh Joshi1,4*
In addition to the psychological depressive phenotype, major depressive disorder (MDD) patients 
are also associated with underlying immune dysregulation that correlates with metabolic syndrome 
prevalent in depressive patients. A robust integrative analysis of biological pathways underlying the 
dysregulated neural connectivity and systemic inflammatory response will provide implications in the 
development of effective strategies for the diagnosis, management and the alleviation of associated 
comorbidities. In the current study, focusing on MDD, we explored an integrative network analysis 
methodology to analyze transcriptomic data combined with the meta-analysis of biomarker data 
available throughout public databases and published scientific peer-reviewed articles. Detailed gene 
set enrichment analysis and complex protein–protein, gene regulatory and biochemical pathway 
analysis has been undertaken to identify the functional significance and potential biomarker utility 
of differentially regulated genes, proteins and metabolite markers. This integrative analysis method 
provides insights into the molecular mechanisms along with key glycosylation dysregulation 
underlying altered neutrophil-platelet activation and dysregulated neuronal survival maintenance and 
synaptic functioning. Highlighting the significant gap that exists in the current literature, the network 
analysis framework proposed reduces the impact of data gaps and permits the identification of key 
molecular signatures underlying complex disorders with multiple etiologies such as within MDD and 
presents multiple treatment options to address their molecular dysfunction.
Abbreviations
MDD  Major depressive disorder
ADD  Anti-depressant drugs
DEGs  Differentially expressed genes
GSEA  Gene set enrichment analysis
PTM  Post translational modification
GWAS  Genome-wide association studies
Depression and other common mental disorders constitute half of the leading causes of disability  worldwide1. 
It has recently been suggested that mental illness accounts for 32.4% of years lived with disability and 13.0% of 
disability-adjusted life-years and an estimated cost in excess of £2 billion and US$ 40 billion every year for the 
employees in United Kingdom and United States  respectively2,3. Among different forms of mental disorders it is 
estimated that depression disorders (a mood disorder included in Diagnostic and Statistical Manual of Mental 
Disorders: DSM), is prevalent in ~ 4.4% of world  population1. Studies examining long-term mortality trajectories 
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consider major depressive disorder (MDD), a major form of depressive disorder, as a critical mortality risk 
 factor4. Epidemiological studies have demonstrated that the co-occurrence of diverse components of metabolic 
syndrome (high blood pressure, lipid abnormalities, hyperglycaemia and central obesity) with MDD, is associ-
ated with a fourfold increased risk of cardiovascular  disease5–7. Diverse factors attributed in the development of 
MDD include somatic illness, early life  stress8, socioeconomic  factors9, and genetic  factors10. Depending on the 
subtype of MDD (e.g., melancholic, psychotic, catatonic, and atypical depression)11 as well as diverse contribut-
ing factors, depressive symptoms are typically manifested as physical and emotional exhaustion, lack of interest 
or anhedonia, insomnia, impaired concentration, cynicism (depersonalization), and culminate in psychophysi-
ological endpoints such as suicidal ideation and  behaviour12,13.
An appreciation of the complex relationship between the clinical symptoms of MDD and its underlying 
causal biomolecular network is crucial for disease diagnosis as well as clinical management of the disease. 
Network biology based approaches, coalescing diverse OMICs data with biomolecular interaction networks, 
have emerged as a powerful integrative and systems-level approach in understanding complex disease-disease 
and disease-biomolecular  associations14–16. When applied, such an analytic approach involves a dimensional-
ity reduction of altered state of biomolecules to more comparable and interpretable set of biological pathways 
or molecular network information, providing significant insight into the biological mechanisms underlying 
a disease  pathology17–20. Such integrative network analysis approaches have significantly aided in identifying 
putative diagnostic biomarkers, therapeutic targets and pathophysiological mechanisms underlying complex 
 diseases21–23. Furthermore, the continued generation of large and publicly-available ‘omic’ data resources makes 
real the opportunity to examine complex disorders through a tiered systems biology approach, combining data 
collected across independent groups of individuals to identify novel biological parameters and potential causa-
tions, aiding to greater clinical interpretation and management. Complex neuropsychiatric diseases such as 
MDD, attributed by etiologic heterogeneity and a major comorbid risk factor for metabolic  syndrome24, can be 
examined and elucidated at a greater molecular level by such an integrative systems biology  approach25.
A number of studies had proposed comprehensive analysis framework at the systems level for characterizing 
functional biological pathways of candidate genes, proteins and metabolites in  MDD26–31. The findings and of 
these studies, focusing on identifying diagnostic markers and pathophysiological mechanisms associated with 
the symptoms of MDD revealed a bidirectional interaction between systemic stress, chronic low grade inflamma-
tory response, altered neuronal pathways and synaptic signaling in the  pathogenesis28–31. Accumulating evidence 
suggest that the etiopathogenesis of MDD largely involve biochemical abnormalities in monoaminergic systems 
(serotonin, norepinephrine, and dopamine), glutamatergic neurotransmission, and structural abnormalities in 
the prefrontal projection  systems32–34. The majority of these pathway-centric enrichment analysis methods has 
largely been dependent on comprehensive sets of online databases, which differ significantly in terms of repre-
sentation of biological pathways and statistical enrichment analysis  conducted35. Additionally, these databases 
often under represents or lack the relevance of post-translational modifications (PTM), a critical regulator of core 
biological pathways under health and disease conditions. For example, emerging data indicate alteration in glyco-
sylation PTM, a critical modulator of neuronal functions and immune  responses36–38, to be significantly correlated 
with the inflammatory phenotype observed in MDD subjects. As examples of altered glycosylation, levels of the 
sialylated glycan structure Neu5Acα2-6GalNAc on plasma  proteins39, high branching plasma N-glycans with tri 
and tetra-sialylation in males and monogalactosylated N-glycome on IgG4 subclass in  females40, non-fucosylated 
biantennary glycans as well as α1-3-fucosylated triantennary glycans have all been shown to be significantly 
correlated with inflammatory cytokines and pathways in MDD  subjects41. Moreover, majority of the systems 
biology approaches focusing primarily on transcriptomic or genomic data driven pathway enrichment analysis, 
often lack integration of non-genetic molecular measurements generated from the clinical samples. These data 
resources often available in the form of evidence based umbrella reviews; meta-analysis or systematic reviews 
provide a reliable source of molecular markers that are significantly associated with the disease phenotype.
In the current study, an integrative network analysis framework for the detailed biological process enrichment 
analysis to compile a comprehensive coverage of core biological processes associated with the MDD phenotype 
was undertaken. Diverse publicly available transcriptomic datasets associated with the MDD phenotype along 
with reported protein and metabolite markers, where subjected to detailed biological process enrichment analysis. 
In parallel and to compliment these datasets the biological role and significance of glycosylation PTM (lectins as 
well as glycoconjugate structures) was undertaken and integrated into the network analysis to assess correlation 
with the neurological function and inflammatory responses which are reported cellular dysfunctions in MDD 
 subjects32–34,42–50.
Methods
The design methodology explored for the integrative analysis encompassing transcriptomic assessment, reported 
bibliographic databases, open knowledge platforms and ‘omic’ databases is depicted in Fig. 1. The goal was to 
evaluate the functional significance and potential of this methodology in the identification of molecular function 
and biological pathway association of genes, proteins and metabolites for MDD, extending to the examination 
of the role of glycosylation PTM.
Gene expression data selection, bibliographic search and knowledge databases. For the tran-
scriptomic analysis, public database Gene Expression Omnibus (GEO) (https:// www. ncbi. nlm. nih. gov/ geo/) 
was queried using the key word “Major Depressive Disorder”. Datasets included both blood and brain samples 
from MDD subjects and only those datasets with ≥ 3 replicates for both test and control samples were consid-
ered. Datasets without gene annotation were excluded from the analysis. For understanding the gene expression 
changes under treated conditions, data obtained from MDD subjects treated with anti-depressants drugs (ADD) 
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were also included (using the generic names of ADD, Suppl. Table 1). As the number of significant datasets was 
low, data generated in cell line and in vivo model system were incorporated. For data processing and gene anno-
tation, online software tools GenePattern (http:// softw are. broad insti tute. org/ cancer/ softw are/ genep atter n/)51 
and Galaxy (https:// usega laxy. org/)52 were used throughout, following the procedures detailed in user manuals. 
In GenePattern, preprocessing of RNA-Seq data including normalization, missing value imputation, collapsing 
multiple probe set expression values into a single expression values were performed using the VoomNormalize 
(v2); ImputeMissingValues and CollapseDataset modules respectively. Differential expression of the preproc-
essed data files were then performed for individual datasets using the ComparativeMarkerSelection  module53. 
While, in Galaxy the limma-voom tool was utilized for the differential expression analysis accepting the default 
Trimmed Mean of M values (TMM) normalization method and applying filters to remove lowly expressed gene 
in each datasets selected for the analysis (we choose to retain genes if they are expressed at a counts per million 
above 0.5 in at least three samples). Significance of marker genes were calculated using default p-value adjust-
ment methods in  analysis54. For few datasets normalized, log2 transformed gene expression matrix files were 
used directly from the GEO databases, wherever available.
A systematic query of the PUBMED bibliographic  database55 using the search query [“major depressive dis-
order” (Title/Abstract)] AND [biomarker(Title/Abstract)] was performed. After filtering results using “review 
paper” and “full text” as parameters, a comprehensive umbrella review by Carvalho et al.56 was identified report-
ing evidence based correlation of protein and metabolite markers for the 5 most prevalent and high burden major 
mental disorders. An Umbrella review systematically evaluates and collects information from multiple systematic 
reviews and meta-analyses on all outcomes of a given topic for which these have been performed, eliminating 
or greatly reducing reporting  bias57. From Carvalho et al., protein and metabolite markers reported with ‘strong 
correlation’ with the MDD phenotype was presented for integrative analysis.
Through PsyGeNET (Psychiatric disorders Gene association NETwork), genetic markers reported to be asso-
ciated with MDD phenotype were  compiled58. Genetic variants from a published meta-analysis of 130,644 MDD 
 cases59 was also examined for detailed functional genomic data enrichment analysis to build a comprehensive 
pathway coverage of reported genetic and non-genetic markers associated with MDD.
Glycosylation process related gene pool. For the gene expression analysis of glycosylation process 
related genes, the GlycoGAIT  database60, an interactive web database developed within our research group was 
utilised. For this analysis, the GlycoGAIT database was enriched through manual capturing of enzymatic reac-
tions for the glycosyltransferase and glycosidase enzymes, which were extracted from the BRENDA enzyme 
database (https:// www. brenda- enzym es. org/ index. php) and ExPASy bioinformatics resource portal (https:// 
www. expasy. org/). For a number of interactions, where the reaction information is not available, interactions 
were curated manually from PUBMED sources. The reaction formats as well as the substrate and ligand short 
form representation are manually formatted to make it consistent throughout. Information on proteoglycan 
genes were extracted from the HGNC database (https:// www. genen ames. org/). For linking glycosylation reac-
Figure 1.  A flowchart depicting the sequential steps adopted in the current study for the integrative data 
analysis methodology. Various online software analysis tools as mentioned in the diagram were leveraged along 
with our proprietary GlycoGAIT database for detailed gene set enrichment analysis, complex protein–protein, 
gene regulatory and biochemical interaction pathway analysis.
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tions to glycan structure predictions, well characterized human glycan epitope structures were also captured by 
manually selecting epitope structures from the GlycoEpitope database (https:// www. glyco epito pe. jp/ epito pes/ 
epito pe_ list). This list was further enriched with additional epitope structures reported to be present on immune 
cells from published literature  sources61–64.
Nomenclature mapping and gene family association. Prior to enrichment analysis, mapping of 
entity names to their respective standard nomenclatures were performed for metabolite entities using Chemical 
Translational Service (http:// cts. fiehn lab. ucdav is. edu/) and for the protein and gene entities using the multi-
symbol checker tool in HGNC database. This standard nomenclature mapping ensures no metabolite, protein 
or gene markers are missed during the enrichment analysis due to name mismatching. For detailed enrichment 
analysis, the dimensionality of the differentially expressed genes (DEGs) were reduced by generating smaller 
subset of more closely associated genes through mapping individual genes to respective gene families using the 
BioMart software available through HGNC web interface (https:// bioma rt. genen ames. org/). Top ranking gene 
family clusters were then identified from this list using the built-in statistical function in Excel “RANK function”.
Gene set enrichment analysis, cellular process mapping and network visualization. Func-
tional enrichment analysis of the literature based protein markers was performed using the open-source soft-
ware and web server—gProfiler65. The HGNC gene symbol of the proteins were used as the query in the g:GOST 
functional profiling interface in gProfiler using Homo sapiens as the organism species, g:SCS threshold as the 
significance threshold and the user-defined p-value threshold as 0.05 in the advanced options (Suppl. Table 2a). 
Similarly, for the literature based metabolite markers enrichment analysis was performed using the web-based 
analytical pipeline for high-throughput metabolomics data analysis—MetaboAnalyst66 and the Consensus-
PathDB—(CPDB—http:// cpdb. molgen. mpg. de/)67. For the enrichment analysis, metabolite name mapping 
was performed manually to their respective KEGG, PUBCHEM and HMDB  IDs68–70. Due to greater coverage 
we used CPDB for subsequent analysis by inputting the KEGG IDs using the overrepresentation analysis for 
metabolite set function. The default list of 13 pathway-based databases were selected with a p-value cutoff 0.01.
For gene set enrichment analysis (GSEA), HGNC gene symbols of the DEGs were used as the query input in 
the enrichment analysis tools such as the ‘analysis’ feature available in the Enrichr  tool71 or the ‘over-represen-
tation analysis’ feature available in  CPDB67. Besides, the induced network module analysis feature in CPDB was 
also used for identifying possible functional relationship between DEGs such as protein–protein, gene-protein 
and protein-metabolite reactions. The interaction network model generated for the DEGs is extracted as an 
XML-based file format using the CPDB visualization interface and ran through Cytoscape software (http:// www. 
cytos cape. org/)72 for network visualization and analysis. The interaction edges are colored based on the nature 
of interaction and size of each node in the network is adjusted based on “neighborhood connectivity” wherein 
small size represents less connected entities and large size represents highly connected entities. Colours of the 
nodes are adjusted based on gene expression data.
Results
Functional enrichment analysis of markers identified from literature sources and knowledge 
databases. From the meta-analyses review published by Carvalho, et al.56, 7 protein markers and 10 metab-
olite markers were identified that were significantly associated with MDD subjects. Functional enrichment anal-
ysis of these protein markers revealed cell proliferation, cell differentiation and growth factor signaling pathway 
as the major categories of biological pathways represented by the protein markers. Similarly, for the metabolite 
markers result obtained from the CPDB and MetaboAnalyst platform was primarily enriched in pathways asso-
ciated with amino acid, nicotinamide, arachidonic acid and antioxidant metabolism (Suppl. Tables 2a, 2b, 2c; 
Suppl. Fig. 1). Biological processes identified from the enrichment analysis of the 62 genetic markers from the 
PsyGeNet database were broadly related to synaptic signaling, neurotransmitter metabolic process, neurotrans-
mitter transport and neuron development (Suppl. Table 3a,b). Additional enrichment analysis of genetic vari-
ants identified from a recently published meta-analysis of 130,644 MDD  cases59 was performed. 67 gene were 
identified from this study, which either contain or are in linkage disequilibrium with a reported single nucleotide 
polymorphism. The GO biological process association of these gene markers were significantly enriched with the 
neuron generation and development processes (Suppl. Table 4a,b).
Differentially expressed genes. Using Comparative Marker Selection model (Genepattern software) for 
the microarray data and Limma-voom model (Galaxy Version 3.34.9.7) for the high throughput sequencing 
 data73,74, 8 out of 22 datasets were identified (Suppl. Table 5) that contained significantly differentially expressed 
genes (DEGs) based on the filter criteria set out (p ≤ 0.05 uncorrected, FDR corrected at p ≤ 0.1). The selected 
datasets from MDD subjects includes 4 datasets generated from the blood samples and 2 datasets from the 
brain hippocampus and prefrontal cortex regions. To compare the gene expression pattern under pathological 
and treated conditions, transcriptomics data under ADD treated conditions were also included in the analysis. 
However, owing to the current lack of datasets from the brain samples, only two datasets from the blood samples 
of ADD treated MDD subjects were included within the analysis undertaken. The DEGs identified after the 
filtering were further narrowed down by applying a cut-off value of ~ twofold up or down regulated genes. The 
resultant DEGs were pooled into three categories (Suppl. Table 6), based on the sample sources and types, which 
is as, detailed below:
 (i) Blood samples, untreated—228 upregulated genes and 198 down regulated genes.
 (ii) Brain samples, untreated—608 upregulated genes and 738 downregulated genes.
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 (iii) Drug treated, blood samples—215 upregulated genes and 129 downregulated genes.
Gene family association and GSEA of DEGs. DEGs from the blood and brain samples of MDD sub-
jects and from the blood samples of ADD treated MDD subjects were mapped to their respective gene families 
(Suppl. Table 7a). Among these, the top ranking gene families were identified by applying a cut-off value of ≥ 5. 
This method enabled to systematically narrow down the significant DEGs which covered ~ 14% to 22% of the 
genes across three sample categories which include (i) 46 upregulated and 42 downregulated genes from the 
blood samples (ii) 98 upregulated genes 115 downregulated genes from the brain samples (iii) 47 upregulated 
genes 27 downregulated genes from the drug treated blood samples. A limited number of significant glycogenes 
were identified among the DEGs across the three data categories, with maximum representation from the brain 
samples (Suppl. Table 7b).
Glycosylation process related gene pool. GlycoGAIT database, compiled together from multiple 
online databases, captures 564 proteins which represents the unique list of well characterized unique list of 
lectins, enzymes, transporters and other proteins involved in glycosylation PTM along with a list of 38 genes 
categorized as proteoglycans (Suppl. Tables 8–10), collectively referred to as glycogenes hereafter. Information 
on 331 glycosylation reactions that represent 53 glycosylation reaction patterns in the network format (Suppl. 
Tables 11, 12) are also incorporated.. In addition to glycosylation reactions, the GlycoGAIT database also cap-
tured 194 well-characterized glycan epitope structures (Suppl. Table 13).
Enrichment analysis of DEGs—blood samples of MDD subjects. GSEA and the GO biological pro-
cess overlap analysis of the top ranking clustered gene families (cut off value ≤ 5) for the blood sample DEGs 
primarily showed enrichment of immune signaling pathways such as cellular response to cytokine stimulus, 
positive regulation of immune response, platelet activation, neutrophil mediated immunity, markers of mye-
loid—lymphoid maturation, complement—coagulation cascades and glycosaminoglycan metabolism. Key cel-
lular processes identified for the glycogene subset involve mucin type O-Glycan biosynthesis and chondroitin 
sulfate/dermatan sulfate metabolism (Suppl. Table 14). Significant gaps in process association was observed in 
various pathway databases for the glycogene subsets.
Molecular mechanisms underpinning the GSEA results and the over-representation analysis results were 
studied by using the induced network module available in  CPDB67. The interconnected network revealed a 
strong inflammatory signaling pathway comprising of immunomodulatory receptors, guanine exchange factors, 
adaptor proteins and non-receptor tyrosine kinases (Fig. 2). Downregulated genes, identified to be linked with 
this inflammatory signaling cascade, comprised of primarily markers of myeloid and lymphoid maturation that 
belongs to cluster of differentiation  family75–79; few anti-inflammatory proteins such as PILRA (paired immuno-
globin like type 2 receptor alpha)80, SLAMF7 (SLAM family member-7)81 and LILRA3 (leukocyte immunoglobu-
lin like receptor-A3)82. Other category identified from this group consist of proteins involved in cell adhesion 
and migration such as PLAUR (plasminogen activator, urokinase receptor)83, CLEC4E (C-type lectin domain 
family 4 member E)84 and ICAM1 (intercellular adhesion molecule-1)85.
Protein–protein interaction network captured the association of glycogene DEGs majorly with the anti-
coagulant protein PLAUR 86 and the Integrin signaling cascade (Fig. 2). Binary interaction network between the 
upregulated glycogene GALNT14 and the proteoglycan VCAN (versican) with the SELPLG (selectin P ligand)—a 
critical protein involved in leukocyte  trafficking87, might indicate enhanced signaling pathways for leukocyte 
adhesion. Tyrosine sulfation of leukocyte adhesion molecules, chemokines and chemokine receptors has been 
implicated in promoting atherosclerosis by enhanced recruitment of mononuclear  cells88,89 and is captured in 
the network model as a protein–protein interaction between TPST1 (tyrosylprotein sulfotransferase-1) and 
the chemokine receptor CCR2. One of the most striking observations in the downregulated glycogene subsets 
was the decreased expression of enzymes such as DSE (dermatan sulfate epimerase), CHST12 (carbohydrate 
sulfotransferase-12) and UST (uronyl 2-sulfotransferase) involved in chondroitin/dermatan sulfate biosynthesis, 
the two immunomodulatory  glycosaminoglycans90–94.
Significant gap in enrichment analysis databases were identified for a number of glycogenes in the blood sam-
ple DEGs. These glycogenes, which are reported to be critical regulators of inflammatory responses, involve OGA 
(O-GlcNAcase) and B4GALT5 (β-1,4-galactosyltransferase-5)95–99. Other few important glycogenes identified 
in this category are lectins involved in the plasma protein clearance, immune cell adhesion and anti-coagulant 
properties such as C-type lectin receptors ASGR1 (asialoglycoprotein receptor-1), DGCR2 (DiGeorge syndrome 
critical region gene-2) and thrombomodulin (THBD)100,101.
Enrichment analysis of DEGs—brain samples of MDD subjects. Carrier and channel proteins 
involved in ion coupled cell transport mechanisms, growth factor signaling pathways as well as protein coding 
genes involved in neurotransmission and synapse formation were some of the top scoring enriched processes 
identified from the GSEA and the GO biological process analysis. Similarly, glucose, sialic acid, glycosphin-
golipid and glycosaminoglycan metabolism, glycosylphosphatidylinositol (GPI) anchor and O-glycan biosyn-
thesis were the top scoring enriched processes for the glycogene subsets. Few biological processes associated 
with ion homeostasis, chemokine mediated signaling pathway, cellular response to cytokine stimulus, ubiqui-
tination, RNA metabolic and biosynthetic processes were also identified from these DEGs (Suppl. Table 15).
A unique list of 243 DEGs were selected for the induced network model based analysis which extracted a 
highly interconnected transcriptional network with the ubiquitination machinery, neurotransmitter and ion 
homeostasis transporters as well as adhesion molecules (Fig. 3). It may be interesting to evaluate whether the 
altered transcriptional signatures and its regulatory interaction network with the transporter machinery might 
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explain the decreased norepinephrine, GABA and increased levels of glutamate neurotransmitters observed 
in MDD  subjects102–105. Moreover, DEGs representing the Fibroblast growth factor (FGF) signaling pathway, 
dysregulation of which was associated with the anxiolytic and antidepressant function with severely depressed 
 humans106, were found to be connected with the ubiquitination and the solute carrier family proteins in the 
network. Similarly, the upregulated expression pattern of neuropeptide GAL (galanin) among the DEGs was 
consistent with a previous  report107 and might indicate dysregulation in pathways involved in mood regulation.
Focused analysis of the glycogene DEGs enabled us to identify few of them to be associated with the transcrip-
tional hub machinery (Fig. 3). These genes are primarily involved in the complex N-glycan synthesis, heparan 
sulfate biosynthesis, ganglioside metabolism, GPI-anchor biosynthesis processes and polysialic acid modifica-
tion of neuronal cell adhesion  molecules108. The decreased expression of ST8SIA3 (ST8 α-N-acetyl-neuraminide 
α-2,8-sialyltransferase-3) involved in the synthesis of c-series ganglioside and HEXB (heoxsaminidase) enzyme 
involved in regulating GM2 ganglioside content, might indicate altered neuronal  repair109 synaptic plasticity and 
 neurogenesis110,111. Interestingly, in the network model, HEXB gene was associated with the hypoxia regulated 
hexokinase isoform HK2 and glucokinase enzyme GCK, which are critical regulators of glucose  metabolism110 
and hence might indicate a role of adaptive mechanism to support brain energy metabolism. Similarly, downregu-
lated expression pattern of gene transcripts involved in the GPI-anchor biosynthesis pathway: PIGN (phosphati-
dylinositol glycan anchor biosynthesis class N) and PIGF (phosphatidylinositol glycan anchor biosynthesis class 
F) might indicate altered cell surface expression of various proteins that play vital role in neuronal differentiation, 
synapse development as well as axon  guidance110,112–114.
Enrichment analysis of DEGs—blood samples of ADD treated MDD subjects. GSEA and GO 
biological process categorization of DEGs from the blood samples of ADD treated MDD subjects highlighted 
phagosome formation, endosomal/lysosomal pathways, positive regulation of cell death and immune responses, 
antigen processing and presentation, as some of the top scoring enriched pathways. While, for the downregu-
lated gene subsets this include spliceosome, histone modification, mRNA processing, organic cyclic compound 
or cellular nitrogen compound metabolic process and DNA damage. Similar analysis for the glycogene DEGs 
yielded sialic acid metabolism, O-linked glycosylation and glycosaminoglycan metabolism as the major enriched 
cellular processes (Suppl. Table 16).
DEGs from the top ranking gene family clusters were subjected to induced network model based analysis 
by seeding 83 unique gene list integrated from the upregulated and downregulated gene lists, including the 
Figure 2.  Network visualization of the integrated network module of both upregulated and downregulated 
genes identified from the blood samples of MDD patients. The interaction network is generated using the 
CPDB induced network modules by inputting the gene subsets from the top ranking gene family clusters along 
with the glycogenes. The compact subnetwork is created by applying a z-score threshold of 20 in the CPDB 
user interface. Exported network model from the CPDB is processed in the Cytoscape visualization tool using 
GeneMANIA Force Directed Layout and the entities are manually aligned. Colours of the nodes are adjusted 
based on gene expression data wherein wine red colour represents upregulated genes and dark green represents 
the downregulated genes. Major network modules with maximum representation of the DEGs are highlighted in 
the graph using a light yellow background.
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glycogenes. Induced network model based analysis using CPDB generated protein–protein interaction networks 
linking chromatin remodeling and spliceosome machineries with the proteins involved in antigen presentation 
and immunomodulatory receptor signaling pathways (Fig. 4). Additional literature search on the entities of 
this seed network suggests a change in the innate immune response  pathway115–119 as well as co-stimulation of 
antigen activated  lymphocytes120 under drug treated condition, which need to be studied in detail. Decreased 
expression pattern of the linker histones associated with chromatin modification (Fig. 4) suggest that epigenetic 
modifications are involved in gene expression  reprogramming121 under drug treated conditions in the peripheral 
blood mononuclear cells.
Interestingly, among the glycogenes two major glycosyltransferases FUT7 (fucosyltransferase-7) and 
ST3GAL4 (ST3 beta-galactoside alpha-2,3-sialyltransferase-4) were found to be upregulated and was linked 
with the TLR and HLD-DRA protein entities (Fig. 4). Another important gene which was found to be upregulated 
and code for the poly-N-acetyllactosamine synthesizing enzyme, B3GNT8 (UDP-GlcNAc:betaGal-β-1,3-N-acet
ylglucosaminyltransferase-8), was not found in the induced network model. Due to lack of sufficient informa-
tion in the induced network model, detailed analysis of the enzymatic reaction and possible glycan structure 
formation for these enzymes were performed using the GlycoGAIT reaction database. From the reaction table 
these three enzymes were mapped to 19, 25, 32 and 45 reaction codes (Suppl. Table 12). Manual search for the 
maximum combination of these reaction codes in the epitope table, lead to the identification of possible glycan 
epitope structures and were mapped to  Lewisa-  Lewisx  (Lea-Lex), 3′-sialyl  Lea-Lex (3′sLea-Lex), 3′s-Di-Lea), 3′s-Di-
Lex, O-Fucose Glycan /EGF Repeat, Sialyl 6-Sulfo LacNAc, Sialyl 6-Sulfo  Lex,  sLea,  sLex,  sLex-i, VIM-2 (CD65, 
CDw65,  sLei-x) and Myeloglycan structures (Suppl. Table 13). The sialylated Lewis-type blood group antigens 
as well as the myeloglycan or the polylactosaminolipid structures are known to modulate immune function in 
both myeloid and lymphoid  cells122–125.
Discussion
Diverse integrative network analysis approaches have been adopted in the past to identify the aberrant pathway 
networks underlying complex diseases by leveraging multiple “-omic”  studies126. Similar integrative analysis is 
required to understand the biological implications underlying the phenotypical and physiological expression of 
complex disorders such as MDD. In addition to the depressive phenotype, MDD subjects are also associated with 
underlying immune dysregulation, which has been shown to correlate with the metabolic syndrome prevalent 
in MDD subjects presenting a complex biomarker  network127.
Figure 3.  Integrated network model generated for both upregulated and downregulated genes identified from 
the brain samples of MDD patients using the CPDB induced network modules. The current network model 
comprises of 218 nodes out of the 243 input genes from the top ranking gene family clusters along with the 
glycogenes. The compact subnetwork is created by applying a z-score threshold of 20 in the CPDB user interface. 
Exported network model from the CPDB is manually aligned in the GeneMANIA Force Directed Layout using 
the Cytoscape visualization tool. Colours of the nodes are adjusted based on gene expression data wherein 
wine red colour represents upregulated genes and dark green represents the downregulated genes. The DEGs 
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The undertaking to compile all available data for network and systems biology studies for a single disorder is 
not a trivial task, limited by analysis and computational techniques currently available, and by the complexity of 
biological interaction and network. The potential to introduce bias, impacting observations and reported findings 
exists across all integrated and systems biology networks being subjected to numerous independent datasets, 
subject to different classification and as is the current case with MDD small-sample datasets. Limitations suffered 
in common across such studies include, (i) restrictions on the basis of inclusion through the use of keywords and 
terms; (ii) limited datasets and their size and classification; (iii) sampling and confounding factors; (iv) limiting 
analysis to top ranked findings, potential missing key molecular interactions as network noise, analysis threshold; 
(v) subject to level of detail and biological functions assigned in databases.
A number of knowledge databases focusing on MDD as well as molecular meta-analysis data are currently 
 available26,27,128–131. There are however, several challenges in the integration of omics data within a network. These 
extended to but not limited to include experimental and inherent biological noise, differences among experi-
mental platforms, detection bias, and unclear molecular cascades and mechanisms. A common trend, reporting 
the significant gap in correlation of both genetic and non-genetic biomarkers with the MDD phenotype also 
 exists132,133. Commencing this study, a recent umbrella review was selected to give an evidence-based correlation 
of both proteins and metabolite markers for  MDD56. Functional enrichment analysis of the MDD associated 
peripheral markers from this study revealed enrichment of cellular processes associated with inflammatory 
response, endothelial dysfunction and neurological functions suggesting a close interrelationship between these 
biological events in MDD condition, which might drive these patients to higher risk of depressive symptoms 
and metabolic  syndrome134,135.
From the blood samples of MDD subjects’, gene expression patterns indicated heightened inflammatory 
signaling pathways and decreased myeloid and lymphoid maturation as well as anti-inflammatory pathways. 
Results summarized in this study are consistent with the recent findings of increased neutrophil to lymphocyte 
ratio, platelet volume and activity in MDD  subjects5,77,136,137. Further to, downregulated gene transcripts iden-
tified from the blood samples mapped to complement—coagulation cascades indirectly indicating reduced 
anti-coagulant activity in MDD subjects. A recent proteomic investigation of plasma based biomarkers in MDD 
subjects also reported increased expression of proteins involved in coagulation  cascades138 which might lead to 
prothrombotic platelet phenotype as demonstrated in a study by Lopez-Vilchez et al.13. These findings coincide 
Figure 4.  Integrated network model of 82 DEGs from the top ranking gene family clusters identified from 
the blood samples of anti-depressant drug treated MDD patients using the CPDB induced network modules. 
The compact network model is created by applying a z-score threshold of 20 in the CPDB user interface. 
GeneMANIA Force Directed Layout in the Cytoscape visualization tool was used for manually aligning and 
analyzing the exported network from CPDB. Colours of the nodes are adjusted based on gene expression data 
wherein wine red colour represents upregulated genes and dark green represents the downregulated genes. 
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with the inflammation theory of depression, which suggests a neuro-inflammatory circuit that underlies the 
development of  depression139–141.
Gene expression pattern from the brain samples revealed dysregulated neuroprotective mechanisms. The 
altered gene expression markers of mRNA splicing, translational machinery and ubiquitination machinery, from 
the brain samples, might indicate an enhanced cellular stress level and altered gene transcription reprogramming. 
Current analysis, revealed several gene expression markers that correlate with altered levels of neurotransmitters 
and dysregulated neuronal ion homeostasis which might indicate defective neuron myelination and synaptic 
 signaling10,103–106,142 in MDD subjects. Moreover, the genetic findings from a recent GWAS indirectly supports 
our methodology as the results obtained here in the current analysis were majorly associated with cytokine and 
immune responses in addition to neuronal development and morphogenesis, showing strong parallel with the 
 GWAS59.
In order to understand the impact on gene expression patterns by ADD treatment, relevant gene expres-
sion data were queried from the public databases. In this regard, one of the major limitations is in the lack of 
availability of sufficient brain sample data from ADD treated MDD subjects. DEGs identified from the blood 
samples of different ADD treated MDD subjects highlight primarily an increase in innate immune response 
pathway with co-stimulation of antigen-activated lymphocytes. Whether these pathways drive specifically the 
anti-inflammatory signaling or augment the innate immune response is not clear but this possibility has been 
proposed and it needs more detailed research to support this hypothesis. A recent systematic review which 
studied the impact of ADD on innate and adaptive immunity by Bournazos et al., reported high heterogeneity in 
results and small number of comparable  studies143. Considering the limited availability of drug treated samples, 
studies that are more detailed are required to delineate the molecular mechanisms underlying the impact of 
ADD on immune response pathways, which is considered as one of the factors that underlie treatment-resistant 
depression in MDD  subjects144.
Within the GSEA and induced network analysis, DEGs related to glycogenes were analysed. Glycosylation 
PTM as well as glycoconjugate structures are known to play crucial role in modulating central and peripheral 
nervous system functions and immune  responses37,145,146. Results obtained from this study revealed significant gap 
in databases that support GSEA for glycosylation process related reaction networks. With the aid of GlycoGAIT 
database and manual literature based analysis, meaningful interpretation for the altered glycogene expression 
was attempted. From the MDD blood samples transcriptional reprogramming of glycogenes that favor pro-
inflammatory response in lymphocytes and monocytes and downregulation of glycosaminoglycans, which have 
anti-inflammatory and anti-coagulant properties, were identified. The gene expression pattern from the brain 
samples indicate increased expression of glycogenes involved in synthesis of sialylated structures which are a 
prominent feature of brain glycoproteins such as those observed on cell adhesion molecules, ion channels and 
many ligand-activated receptors in neuronal and glial  cells38,147. Decreased expression of enzymes involved in 
GPI pathway and in regulation of GM2 ganglioside content might indicate altered brain glycolipid structures, 
which are crucial for synaptic plasticity and  neurogenesis110,111. One of the most interesting aspects of the gly-
cogene expression data analysis was the prediction of sialylated Lewis-type blood group antigens as well as the 
myeloglycan or the polylactosaminolipid structure formation in blood monocytes and leukocytes under ADD 
treatment condition. Hence, it will be interesting to validate how these specific glycan structures fits with the 
anti-inflammatory claim of these  drugs148–151 which can potentially developed as diagnostic markers.
Despite significant advancement in the field of ‘omics’ data analysis and the increasing accessibility to open 
repositories, no central guideline or platform for an integrative analysis framework has yet been proposed for 
standardization. For the continued development and acceptance of validity of integrative analysis, standardization 
at multiple levels is essential. Unlike the analysis of a single dataset, the power of integrative analysis framework 
stems from the fact that multiple independent data sources can be analyzed to explore trends, similarities or 
variations in the behavioral patterns of molecular functions and biological processes, which can be correlated 
with a disease phenotype, outcome and treatment.
The methodology presented here provides an exemplary framework to systematically integrate diverse ‘omics’ 
data in an open, inclusive and unbiased manner. Researchers, without the need for advanced computational 
demands can implement and apply the current approach to available datasets requiring minimal computational 
resources. Presenting a methodological approach, which could be utilized and adapted for exploiting existing 
datasets without requiring field expertise using publically open and available resources and repositories. Present-
ing the inclusion of integrative analysis to become a more routine undertaking and building a mass of analysis 
which can be refined for standardization and proposing validation albeit through replicated integrative studies 
within single conditions. Using such an approach the study provides novel insights into the molecular mecha-
nisms underlying altered immune response as well as dysregulated neuronal survival maintenance and synaptic 
functioning in MDD subjects. Furthermore, for the first time altered glyco-genome expression profile from the 
blood and brain samples of MDD subjects were explored using GlycoGAIT database which might explain the 
relevance of glycoconjugate structures in modulating the immune responses and neuronal functions.
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